Место обратимых ингибиторов рецепторов Р2Y12 при остром коронарном синдроме

1. van Giezen JJ, Nilsson L, Berntsson P et al. Ticagrelor binds to P2Y12 receptors independently from ADP but antagonizes ADP-induced receptor signalling and platelet aggregation. J Thromb Haemost 2009; 7: 1556–65.
2. Сироткина О.В., Богданова Е.В., Боганькова Н.А. и др. Эффективность антиагрегантной терапии клопидогрелом у пациентов, перенесших инфаркт миокарда с подъемом сегмента ST. Кардиоваск. тер. и профилакт. 2009; 8: 51–5.
3. Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312–9.
4. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821–30.
5. Tantry SU, Bliden KP, Wei C et al. First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel: The ONSET/OFFSET and RESPOND. Genotype Circ Cardiovasc Genet 2010; 3: 556–66.
6. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial. N Engl J Med 2001; 345: 494–502. DOI 10.1056/NEJMoa010746.
7. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–33. DOI 10.1016/S0140-6736(01)05701-4.
8. Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–20. DOI 10.1001/jama.288.19.2411
9. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89. DOI 10.1056/NEJ-Moa050522
10. Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pre-treatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224–32. DOI 10.1001/jama.294.10.1224
11. Terpening С. An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events. J Am Board Fam Med 2009; 22: 51–56.
12. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel inpatients with acute coronary syndromes. N Engl J Med 2009; 361: 1045. DOI 10.1056/NEJMoa0904327
13. James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised platelet inhibition and patient outcomes (PLATO) trial. BMJ 2011; 342: d3527.
14. Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery by pass surgery results from the PLATO (Platelet Inhibition and Patient Out- comes) trial. J Am Coll Cardiol 2011; 57: 672–84.
15. Becker RC, Bassand JP, Budaj A et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011; 32: 2933–44.
16. Mahaffey KW, Wojdyla DM, Carroll K et al. on behalf of the PLATO Investigators Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2011; 124: 544–54.
17. Crouch MA, Colucci VJ, Howard PA et al. P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome. Pharmacother 2011; 45: 1151–6.
18. Storey RF, Becker RC, Harrington RA et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011; 32: 2945–53.
19. Briefing information for the July 28, 2010, meeting of the 
Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/Advisory Committees/CommitteesMeetingMaterials/Drugs/Cardiovascularand RenalDrugsAdvisoryCommittee/ucm220190.htm (accessed 2011 Mar 9).

Т.А.Бурякина, Д.А.Затейщиков 

ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва